The FDA on November 25, 2025, approved IMFINZI® with Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by single agent IMFINZI®, for adults with resectable Gastric or GastroEsophageal Junction adenocarcinoma (GC/GEJC). IMFINZI® is a product of AstraZeneca.
Bottom Ad
Advertisement
Subscribe
